Clinical trials: Membranous Nephropathy
Kidney Failure
Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients
The purpose of this study is to determine the quantity of iron derived from SFP that is transferred from the dialysate to patients during a single dialysis session.
- Trial name
- NCT01894906
- Testing
- Soluble Ferric Pyrophosphate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Rockwell Medical Technologies, Inc.
Acute Kidney Injury, Hemorrhage
Efficacy and Safety of Heparin-grafted Membrane for CRRT
The investigators hypothesize that the use of heparin-grafted membrane versus conventional membrane in critically-ill patients with bleeding-risk undergoing continuous renal replacement therapy, will effectively prolong the…
- Conditions
- Acute Kidney Injury, Hemorrhage, Coagulopathy
- Trial name
- CARROM (NCT01779635)
- Testing
- oXiris as first filter, M150 as first filter
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- National University Hospital, Singapore
Kidney Diseases, Acute Injury of Kidney
Hemofilter Life Span, ECLS And/or CRRT
The goal of this project to better understand the immune-modulatory effects of continuous renal replacement therapy (CRRT) in neonatal and pediatric patients, particularly those receiving extracorporeal life support (ECLS).
- Conditions
- Kidney Diseases, Acute Injury of Kidney, Renal Failure, Renal Insufficiency
- Trial name
- NCT04193865
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Medical University of South Carolina
Lupus Nephritis, Primary Membranous Nephropathy
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in…
- Trial name
- NCT06557265
- Testing
- NKX019, Fludarabine, Cyclophosphamide
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 120 people
- Sponsor
- Nkarta, Inc.
Efficacy and Safety
Efficacy and Safety of the Treatment of Primary Membranous Nephropathy: A Randomized Clinical Trial
1. Main purpose: To evaluate the efficacy and safety of rituximab combined with tacrolimus in the treatment of intermediate and high-risk primary membranous nephropathy 2.
- Trial name
- NCT05532111
- Testing
- Rituximab combined with tacrolimus induction + rituximab maintenance, Rituximab combined with tacrolimus induction + tacrolimus maintenance, Glucocorticoid combined with cyclophosphamide induction + maintenance
- Volunteers
- 60 people
- Sponsor
- RenJi Hospital
Tacrolimus, Idiopathic Membranous Nephropathy
Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy
This random, open, control and multicenter clinical trial mainly aims to assess the urine protein remission rate of tacrolimus (TAC) monotherapy for idiopathic membranous nephropathy (IMN).
- Conditions
- Tacrolimus, Idiopathic Membranous Nephropathy, Clinical Trial
- Trial name
- NCT03864250
- Testing
- Tacrolimus, Prednisone
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease
A Study With Imlifidase in Anti-GBM Disease
An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone.
- Conditions
- Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
- Trial name
- GOOD-IDES-02 (NCT05679401)
- Testing
- Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC)
- Where
- 48 sites in United States, Austria and 11 more
- Volunteers
- 50 people
- Sponsor
- Hansa Biopharma AB
Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis
NEPTUNE Match Study
NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.
- Conditions
- Nephrotic Syndrome in Children, Focal Segmental Glomerulosclerosis, Minimal Change Disease, Minimal Change Nephrotic Syndrome
- Trial name
- NEPTUNE Match (NCT04571658)
- Testing
- Communication
- Where
- 16 sites in United States
- Volunteers
- 375 people
- Sponsor
- University of Michigan
Glomerulonephritis
A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy
Membranous Nephropathy (MN) is an immune-mediated kidney disease that affects the glomerulus or the filter that removes toxins from the blood.
- Trial name
- NCT01093157
- Testing
- Adrenocorticotrophic hormone ACTH
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- University Health Network, Toronto
Membranous Nephropathy
Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy
This is a non-pharmacological interventional monocentric study to primarily assess the levels of circulating phospholipase A2 receptor (PLA2R)-specific B cells in patients with PLA2R-mediated MN enrolled in the ORION and MONET…
- Trial name
- DEEPER (NCT06994468)
- Testing
- Flow-cytometry tetramer-based antigen-bait assay
- Where
- Italy
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Mario Negri Institute for Pharmacological Research
Idiopathic Membranous Nephropathy, Proteinuria
A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy
This prospective, randomized, controlled, multicenter clinical trial will evaluate Opportunity, Validity and Security of Steroids Plus Cyclosporin therapy for patients of Idiopathic Membranous Nephropathy.
- Conditions
- Idiopathic Membranous Nephropathy, Proteinuria, Spontaneous Remission, Steroid Nephropathy
- Trial name
- NCT02173106
- Testing
- steroid & Cyclosporin
- Where
- 6 sites in China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University
Primary Membranous Nephropathy
The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy
This is a multiple-center, prospective, open-label, positive drug controlled, randomized, clinical study to evaluate the safety and efficacy of Telitacicept in the treatment of primary membranous nephropathy.
- Trial name
- TEST-T-PMN (NCT06614985)
- Testing
- Telitacicept, Prednisone, Cyclophosphamide
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Renmin Hospital of Wuhan University
End Stage Renal Disease
Efficacy of Uremic Toxins Clearance With Expanded Hemodialysis
The aim of this study is to quantify the B2-microglobulin reduction rate based on the type of extracorporeal therapy (ET) used: HDx (expanded hemodialysis), HDc (high-flux conventional hemodialysis), or HDF (hemodiafiltration).
- Trial name
- NCT04786535
- Testing
- Expanded Hemodialysis, High-flux Conventional Hemodialysis, Hemodiafiltration
- Where
- Mexico
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Systemic Lupus Erythematosus
Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus
The purpose of this study is to determine how the body absorbs and chemically changes a single infusion of TRU-015 in subjects with kidney disease caused by lupus.
- Trial name
- NCT00479622
- Testing
- TRU-015
- Where
- 6 sites in United States
- Volunteers
- 20 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Idiopathic Membranous Nephropathy
Prognostic Model of GC/TAC in the Treatment of MN
The goal of this observational study is to explore the factors that can predict the prognosis difference in patients with idiopathic membranous nephropathy (IMN) under the treatment of glucocorticoid + tacrolimus.
- Trial name
- NCT05667896
- Testing
- glucocorticoid + tacrolimus
- Volunteers
- 50 people
- Sponsor
- Qianfoshan Hospital
Primary Membranous Nephropathy
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
To evaluate the efficacy and safety of B007 in the Treatment of Primary Membranous Nephropathy
- Trial name
- NCT06470191
- Testing
- B007, Cyclosporin Capsules
- Where
- 21 sites in China
- Volunteers
- 216 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd